Aglaia Therapeutics
A biotechnology startup developing promising new therapies that can overcome resistance to current targeted therapies in cancer patients.
Launch date
Market cap
-
Enterprise valuation
$18—26m (Dealroom.co estimates Sep 2021.)
Villejuif Île-de-France (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
€4.0m | Seed | ||
| Total Funding | $4.4m | ||